Ultragenyx Pharmaceutical Inc.

RARE · Nasdaq · United States

Share price · RARE

$17.73-7.76 (-30.44%) 3M

close as of 2026-11-18 · 24h delayed · vol 5.2M (1.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when RARE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 3 Sep 2026-44.0%
  2. 30 Jun 2026+8.8%

    Nothing announced by RARE that day or the session before.

  3. 17 Jun 2026+8.3%

    Nothing announced by RARE that day or the session before.

  4. 19 May 2026-7.2%

    Nothing announced by RARE that day or the session before.

  5. 30 Dec 2025+15.5%
  6. 29 Dec 2025-42.3%
  7. 16 Dec 2025-5.2%

Share of unusual movement by asset

For each asset, the share of RARE's own-move activity since 14 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
setrusumab
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—35%
Other company news (earnings, financing, releases naming no asset)—36%
Sessions with no dated event—29%

Assets

(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Evinacumab(Evkeeza)
Approved
ANGPTL3Monoclonal antibody
Homozygous Familial Hypercholesterolemia
Phase 3
SclerostinMonoclonal antibody
Osteogenesis Imperfecta

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
January 2027 (1)
setrusumabPhase 3Osteogenesis Imperfecta
Est. primary completion 2027-01 · NCT06636071 · CT.gov ↗
What to watch
2028 (1)
October 2028 (1)
Evinacumab · EvkeezaPhase 2Diabetic Kidney Disease (DKD)
Est. primary completion 2028-10-13 · NCT07271186 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 December 2025Topline resultsetrusumabPhase 3 Orbit (NCT05125809) and Cosmic of setrusumab did not meet their primary fracture-rate endpoints

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$173M$154M$150M+ $116M short-term inv.$118M-$43M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$214M$167M$125M+ $167M short-term inv.$92M-$97M operating cash flowreport ↗
2026-Q1$136M$187M$175M+ $238M short-term inv.$185M-$197M operating cash flowreport ↗
2025-Q3$160M$216M$203M+ $223M short-term inv.$180M-$91M operating cash flowreport ↗
2025-Q2$167M$165M$176M+ $311M short-term inv.$115M-$108M operating cash flowreport ↗
2025-Q1$139M$166M$127M+ $367M short-term inv.$151M-$166M operating cash flowreport ↗
2024-Q3$139M$170M$151M+ $471M short-term inv.$134M-$67M operating cash flowreport ↗
2024-Q2$147M$162M$481M+ $283M short-term inv.$132M-$77M operating cash flowreport ↗
2024-Q1$109M$178M$112M+ $300M short-term inv.$171M-$191M operating cash flowreport ↗
2023-Q3$98M$157M$73M+ $370M short-term inv.$160M-$118M operating cash flowreport ↗
2023-Q2$108M$165M$102M+ $450M short-term inv.$160M-$116M operating cash flowreport ↗
2023-Q1$101M$166M$86M+ $544M short-term inv.$164M-$157M operating cash flowreport ↗
2022-Q3$91M$237M$392M+ $497M short-term inv.$245M-$95M operating cash flowreport ↗
2022-Q2$89M$155M$160M+ $383M short-term inv.$158M-$77M operating cash flowreport ↗
2022-Q1$80M$143M$154M+ $444M short-term inv.$152M-$118M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$673M$750M$421M+ $259M short-term inv.$144M-$466M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$560M$698M$174M+ $436M short-term inv.$142M-$414M operating cash flowreport ↗
2023-FY$434M$648M$214M+ $364M short-term inv.$152M-$475M operating cash flowreport ↗
2022-FY$363M$706M$133M+ $615M short-term inv.$177M-$380M operating cash flowreport ↗
2021-FY$351M$497M$308M+ $433M short-term inv.$114M-$339M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 28 sales ($3.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-15Horn Howard · Chief Financial OfficerOpen-market sale7,066$15.27$108KForm 4
2026-09-15Huizenga Theodore Alan · SVP, Chief Accounting OfficerOpen-market sale1,283$13.57$17KForm 4
2026-09-03Huizenga Theodore Alan · SVP, Chief Accounting OfficerOpen-market sale161$13.99$2KForm 4
2026-08-03Horn Howard · Chief Financial OfficerOpen-market sale4,696$24.92$117KForm 4
2026-08-03Parschauer Karah Herdman · EVP and Chief Legal OfficerOpen-market sale1,900$24.92$47KForm 4
2026-07-01Horn Howard · Chief Financial OfficerOpen-market sale4,698$33.13$156KForm 4
2026-06-15Parschauer Karah Herdman · EVP and Chief Legal OfficerOpen-market sale1,899$24.62$47KForm 4
2026-06-15Sanders Corazon (Corsee) D. · directorOpen-market sale2,000$25.05$50KForm 4